Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated ...
When Cindy Mrotek and Katie Glenn became caregivers for their parents with cholangiocarcinoma, but they didn’t just find ...
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating ...
Stacie C. Lindsey is being recognized for her patient advocacy, alignment of research efforts and collaboration among the cancer community. AstraZeneca and Scientific American Custom Media sponsor the ...
The new treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data cited by the comp ...
The Cholangiocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholangiocarcinoma ...
DUBLIN, March 20, 2019 /PRNewswire/ -- The "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers ...
Lytgobi (futibatinib) marks the first medicine launched by Taiho Oncology Europe in the UK (2) For United Kingdom (UK) Trade and Medical Media Only ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback